Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Immunicum AB (publ)
  6. News
  7. Summary
    IMMU   SE0005003654

IMMUNICUM AB (PUBL)

(IMMU)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

12/03/2021 | 02:00am EST

Immunicum AB announced the completion of the Phase Ib portion of the ILIAD study evaluating the Company?s off-the-shelf, cell-based immune primer ilixadencel in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda?) in different cancer indications. All subjects in the Phase Ib portion have completed the initial follow-up period for safety and response evaluation, with a positive safety review by the Data Safety Monitoring Board reported last July. Responses to treatment were observed in patients previously treated with CPIs and not in CPI-naive patients. As the latter was the intended patient population for the Phase II part of the study, the company has made the determination to close the study at this stage and not proceed with the Phase II portion. The Phase Ib ILIAD combination trial included cancer patients eligible for pembrolizumab therapy based on its approved label by the FDA. A total of twenty-one subjects were enrolled: ten of those with types head- and neck squamous cell carcinoma (HNSCC), six with melanoma, two with gastroesophageal junction adenocarcinoma (GEJAC), one with non-small cell lung cancer (NSCLC), one with uterine carcinoma and one with cervical cancer. All patients treated within this study suffered from advanced stage disease and were heavily pre-treated with several lines of treatment. A total of sixteen patients were enrolled that had prior exposure to pembrolizumab and progressed on this checkpoint inhibitor, and five patients were enrolled without any prior exposure to pembrolizumab. Among the ten HNSCC patients enrolled, a partial response was observed in two, with those two having been among a subgroup of six patients that tested negative for human papilloma virus (HPV) and had prior pembrolizumab exposure. Additionally, stable disease was observed in four subjects with prior pembrolizumab exposure. Of those stable disease subjects, one had HNSCC, one had melanoma, one had NSCLC and one had GEJAC. Observed responses in the CPI pre-treated patients will be further evaluated on a case-by-case basis. Of the five patients that were enrolled in the Phase Ib portion of the ILIAD study without any prior exposure to pembrolizumab, none had any observable response. As previously reported, no dose-limiting toxicities were observed in the ILIAD study, up to the highest dose of 20 million cells per injection, and no adverse events were reported which were life-threatening or led to death. Only two severe adverse events (grade 3) related to ilixadencel were reported, which were injection-related reactions. All other reported adverse events related to ilixadencel were mild to moderate.


ę S&P Capital IQ 2021
All news about IMMUNICUM AB (PUBL)
01/11BIOSTOCK : Immunicum can look back on a transformative 2021
AQ
01/05Immunicum Transfers Ownership of Viral Vector Patent to Elicera Therapeutics
MT
01/05Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of paten..
AQ
01/05Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics
AQ
01/05Immunicum AB Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics
CI
01/03Immunicum to Participate in Upcoming Investor and Industry Conferences in January
AQ
2021Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to ..
AQ
2021Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with D..
AQ
2021Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with D..
CI
2021BIOSTOCK : Immunicum finalises phase I ILIAD trial
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -132 M -14,3 M -14,3 M
Net cash 2021 121 M 13,2 M 13,2 M
P/E ratio 2021 -4,82x
Yield 2021 -
Capitalization 649 M 70,7 M 70,6 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 29
Free-Float 40,7%
Chart IMMUNICUM AB (PUBL)
Duration : Period :
Immunicum AB (publ) Technical Analysis Chart | IMMU | SE0005003654 | MarketScreener
Technical analysis trends IMMUNICUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 3,26 SEK
Average target price 8,00 SEK
Spread / Average Target 146%
EPS Revisions
Managers and Directors
Erik Manting Chief Executive & Business Officer
Lotta Ferm Chief Financial Officer
Christine Lind Chairman
Alex Karlsson-Parra Chief Scientific Officer
Jeroen Rovers Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMUNICUM AB (PUBL)-24.04%71
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624